SAVING LIVES
MEDICINE REDEFINED
Innovative, accessible, and life-saving treatments to
redefine care for patients with unmet medical needs.
Engineering the next generation of medicine
AGEM Bio is a therapeutic biotechnology company developing next-generation cell therapies using a proprietary, non-viral genetic delivery platform. Our technology enables the precise engineering of mesenchymal stem cells (MSCs) to deliver life-saving therapeutics, pioneering the MSC 2.0 era of cell therapy.
Our platform is broadly applicable across multiple disease areas, including oncology and regenerative medicine. Our flagship program, AGEM-102, is currently in development for a range of difficult-to-treat solid tumours.
Mesenchymal stem cells are at the forefront of modern cell therapy. By harnessing their intrinsic biological properties and functionalising them for specific disease indications, AGEM Bio aims to unlock new therapeutic possibilities for conditions that remain inadequately treated today.
Technology & Pipelines
We pride ourselves on our unique MSC 2.0 technology, which harnesses the power of our proprietary non-viral gene delivery platform to augment the capabilities of mesenchymal stem cells.
Latest News
NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025
SINGAPORE – In the future, patients who suffer a relapse of the deadliest form of brain cancer may get a second shot at life with the help of a novel gene therapy ...
Engineering mini “bombers” and “cleaners” – How this startup is changing the game to treat aggressive cancers
Backed by SGInnovate under a new scheme that accelerates commercialisation, AGeM Bio is on a mission to tackle some of the world’s deadliest cancers...
New therapy shows promis in treating deadly brain cancer, advanced abdominal cancer
SINGAPORE – A deadly form of brain cancer, glioblastoma, is nearly impossible to get rid of – even after patients undergo surgery to remove parts of the tumour, followed by chemotherapy, radiation therapy...